Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 4/20 | 0.43 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KMO | O15229 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29769166 | 0.78 | TRPA1 (0.46) | NR3C1SLC22A12CYP11B1CYP11B2CYP2A6 | |
| SCHEMBL424964 | 0.78 | TRPA1 (0.46) | NR3C1SLC22A12CYP11B1CYP11B2CYP2A6 | |
| SCHEMBL25512215 | 0.77 | HDAC8 (0.46) | NR3C1SLC22A12CYP11B1CYP11B2CYP2A6 | |
| SCHEMBL29521060 | 0.77 | FGFR1 (0.37) | NR3C1CYP11B1CYP11B2MAPTKDM4E | |
| SCHEMBL171978 | 0.76 | SLC22A12 (0.43) | NR3C1SLC22A12CYP11B1CYP11B2CYP2A6 | |
| SCHEMBL13486145 | 0.76 | NR3C1 (0.61) | NR3C1CYP11B1CYP11B2PGR | |
| SCHEMBL15185701 | 0.76 | SLC22A12 (0.47) | NR3C1SLC22A12CYP11B1CYP11B2CYP2A6 | |
| SCHEMBL15798967 | 0.76 | HDAC8 (0.39) | CYP11B1CYP11B2CYP2A6MAPTHDAC8 | |
| SCHEMBL3657596 | 0.76 | CYP11B1 (0.47) | NR3C1SLC22A12CYP11B1CYP11B2CYP2A6 | |
| SCHEMBL16648362 | 0.76 | SLC22A12 (0.43) | NR3C1SLC22A12CYP11B1CYP11B2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197406-A1 | INDAZOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS FOR USING SAME | 1ST Biotherapeutics, Inc. (KR) | 2025-06-19 | — | — | US | disclosed |
| US-11649255-B2 | Indazoles as hematopoietic progenitor kinase 1 (HPK1) inhibitors and methods using same | 1ST Biotherapeutics, Inc. (KR) | 2023-05-16 | — | — | US | disclosed |
| US-20220098193-A1 | INDAZOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS USING SAME | 1ST Biotherapeutics, Inc. | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11649255-B2 | Indazoles as hematopoietic progenitor kinase 1 (HPK1) inhibitors and methods using same | IP6K1, HIPK1, IP6K3 | NR3C1 1391/4885SLC22A12 4635/4885CYP11B1 1224/4885 |
| US-20220098193-A1 | INDAZOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS USING SAME | IP6K1, HIPK1, IP6K3 | NR3C1 1391/4885SLC22A12 4635/4885CYP11B1 1224/4885 |
| US-20250197406-A1 | INDAZOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS FOR USING SAME | IP6K1, HIPK1, IP6K3 | NR3C1 1507/4885SLC22A12 4690/4885CYP11B1 1381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.